Jennifer E. Friedmann
Montreal, QC H3T1E2, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors.
Journal: Investigational new drugs
Published: May 19, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Journal: Cancer research communications
Published: February 12, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.
Journal: Current oncology (Toronto, Ont.)
Published: October 15, 2024
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
Journal: The Lancet. Oncology
Published: October 14, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
Journal: Journal for immunotherapy of cancer
Published: June 14, 2024
Real-World Evidence of the Impact of the COVID-19 Pandemic on Lung Cancer Survival: Canadian Perspective.
Journal: Current oncology (Toronto, Ont.)
Published: January 16, 2024
The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center.
Journal: Current oncology (Toronto, Ont.)
Published: October 14, 2022
The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review.
Journal: Current oncology (Toronto, Ont.)
Published: September 02, 2021
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
Journal: Journal for immunotherapy of cancer
Published: June 09, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026